June 12, 2025 7:53am

Which way is up? Catalysts needed to assist share pricing direction …

Wednesday marked a losing session, with the S&P 500 snapping its 3-day win streak, as did the Nasdaq; yet the moves were slight

Breaking: The May producer price index (PPI), a measure of final demand prices in the U.S. economy, rose just 0.1% for the month after decreasing 0.2% in April. Economists had been looking for a 0.2% increase for last month.

No false narratives or fake news; to read insights and analysis on the latest sector action, check out Pre-Open Brief

Never leave an investor uninformed!

Remember that overnight and pre-open actions’ futures and markets doesn’t necessarily translate into actual trading in today’s market session.

“I also hate to be so negative or contrarian but, this is a NO spin zone and truth is its product; I can always be WRONG but, I am mostly EARLY!”

My interpretation of the morning’s numbers is written to be informative; it’s built on what happened to make “it” happen today!

 

Wednesday’s night’s … RegMed Investors (RMi) Closing Bell: inflationary econ was soft, thumping markets and tripping sector … https://www.regmedinvestors.com/articles/13955

RegMed Investors (RMi) Research Note: Harvard Apparatus GT (OTCQB): PONZI Scheme at its best or was convicted Bernie Madoff also resurrected … https://www.regmedinvestors.com/articles/13812

 

Thursday: The pre-open Dow futures are DOWN -0.46% or (-196 points), the S&P futures are DOWN -0.30% or (-18 points) and the Nasdaq futures are DOWN -0.20% or ( -44.50 points)

  • Stock futures were weaker even as investors got a batch of PPI data hinting at a solid economy, Thursday, 6/12
  • European stock markets are still in negative territory in mid-morning deals,
  • Asia-Pacific markets trade mixed as investors assess Trump claims of ‘done’ deal with China.

 

Henry’omics: We need to more than consider the economic environment to comprehend the micro re “our” universe of cell and gene therapy companies

  • Wednesday: The Dow closed DOWN -1.10 points or -0.00%, the S&P closed DOWN -16.51 points or -0.27% while the Nasdaq closed DOWN -99.10 points or -0.50%
  • Tuesday: The Dow closed UP +105.11 points or +0.25%, the S&P closed UP +32.93 points or +0.55% while the Nasdaq closed UP +123.75 points or +0.63%
  • Monday: The Dow closed DOWN -1.11 points or -0.00%, the S&P closed UP +5.52 points or +0.09% while the Nasdaq closed UP +61.28 points or +0.30%

Economic Data Docket:  May’s producer price index

  • Economists are expecting the index to show a gain of 0.2% for the period. Subtracting out food and energy, core PPI is expected to show growth of 0.3% on the month.

 

Q2 – June – 1 negative, 1 neutral and 5 positive closes

  • May – 1 market holiday, 10 negative and 11 positive closes
  • Q2 - April – 10 negative and 11 positive closes

 

Companies in my headlights – It’s your decision; I provide ideas and context

I post about “indication intelligence” looking toward investment conferences … to assist investors with insight into sector vulnerabilities and strengths.  A dictionary definition of “indicate” refers to something less than a certainty; an indication could be a signal of being oversold or overbought, a recommendation, or grounds for inferring or a basis for believing.

Better part of valor to not lead any investor to temptation; yet again, I am passing on forecasting the daily indications as to expectation while the aftermarket blanked while the pre-open waits for the …  econs, it is still a mix of ups, downs and just uncertainty

Although: a weak aftermarket and pre-open …

CRISPR Therapeutics (CRSP) closed down -$1.42 with a negative -$0.81 or -1.95% pre-open

Beam Therapeutics (BEAM) closed down -$0.19 with a positive +$0.24 or +1.34% pre-open

Ionis Pharmaceuticals (IONS) closed down -$0.65 with a positive +$0.15 pre-open

 

The BOTTOM LINE: Not a clairvoyant, there are session that are just a flip-of-the-coin

As I ruminated, is the cell and gene therapy sector, a bit over-extended – it seems that Wednesday proved it?

 

June ’25: understand the “flow” of markets, the cell and gene therapy sector and economic karma…

  • 6/11 – Wednesday closed negative with 6 positive, 25 negative and 4 flats
  • 6/10 - Tuesday closed positive with 17 positive, 15 negative and 3 flats
  • 6/9 - Monday closed neutral with 16 positive, 16 negative and 3 flats
  • 6/6 – Friday negative with 4 positive, 28 negative and 3 flats
  • 6/5 - Thursday closed positive with 16 positive, 15 negative and 4 flats
  • 6/4 – Wednesday closed positive with 18 positive, 13 negative and 4 flats
  • 6/3 - Tuesday closed positive with 24 positive, 8 negative and 3 flats
  • 6/2 - Monday closed positive with 25 positive, 7 negative and 3 flats

Reiterating, “There are always some big ifs, especially given some of the headlines that could emanate after a past few months of news flatulence.

  • Still a believer after I wrote, about June… “Get back-in and re-test the sector waters after May’s cell and gene therapy sector ‘s month alternations, nibble!  Some believe in a “June Swoon;” however, June will be no better or worse than any other month. Although, I consider the so-called summer rally after the peripatetic or wandering.”

As always, brace ourself for more volatility, economics and their down trending affect?

Welcome to my world of defining the “grey’ in our universe!

  • The sector is what it is, until it isn’t and even then, it doesn’t seem to be… as NOT much changes as the sector’s share pricing rides the waves of volatility, algorithms, electronic trading and short covering.
  • I am more frequently right than consequentially wrong; if I wanted to be liked, I wouldn’t have been an analyst/journalist.

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. All investments are subject to risks. Investors should consider investment objectives.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.  Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and it’s or their securities.

I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed.